Stockscreener 앱 받기
1.75
0.57%
0.01
시간 외 거래:
1.78
0.03
+1.71%
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
ALLO|Allogene Therapeutics Inc|Price:1.740|Chg%:-0.080 - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO - TradingView
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO) - The Globe and Mail
Allogene reports 31% response rate in renal cancer trial By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Unveils Promising Phase 1 Study Res - GuruFocus
Allogene reports 31% response rate in renal cancer trial - Investing.com
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - The Manila Times
Allogene Therapeutics Announces Journal of Clinical - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Allogene Therapeutics (ALLO) Q3 2024 earnings summary - Quartr
Allogene Therapeutics (ALLO) Proxy filing Summary - Quartr
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals
Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan
Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Roberts Zachary - Moomoo
Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang
Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Forecast — Price Target — Prediction for 2027 - TradingView
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union
Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et
Recent pharma exec shake-ups signal strategic shifts - Pharma Voice
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan
Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):